Acadian Asset Management
ENTA icon

Acadian Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Acadian Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Sell
880,023
-5,103
-0.6% -$68.4K 0.02% 506
2025
Q4 		$13.9M Buy
885,126
+18,089
+2% +$230K 0.02% 407
2025
Q3 		$10.4M Hold
867,037
– – 0.02% 473
2025
Q2 		$6.55M Hold
867,037
– – 0.01% 521
2025
Q1 		$4.78M Buy
867,037
+17,613
+2% +$109K 0.01% 512
2024
Q4 		$4.88M Hold
849,424
– – 0.01% 528
2024
Q3 		$8.8M Hold
849,424
– – 0.03% 368
2024
Q2 		$11M Sell
849,424
-4,472
-0.5% -$60.4K 0.03% 327
2024
Q1 		$14.9M Buy
853,896
+10,952
+1% +$145K 0.05% 232
2023
Q4 		$7.93M Buy
842,944
+294,162
+54% +$2.74M 0.03% 337
2023
Q3 		$6.13M Buy
548,782
+448,201
+446% +$7.22M 0.03% 381
2023
Q2 		$2.15M Buy
+100,581
New +$2.97M 0.01% 672
2022
Q3 		– Sell
-42,640
Closed -$2.02M – 1716
2022
Q2 		$2.02M Sell
42,640
-29,133
-41% -$1.58M 0.01% 631
2022
Q1 		$5.1M Sell
71,773
-60,754
-46% -$3.95M 0.02% 460
2021
Q4 		$9.9M Sell
132,527
-106,113
-44% -$8.33M 0.04% 312
2021
Q3 		$13.5M Sell
238,640
-128,372
-35% -$6.35M 0.05% 262
2021
Q2 		$16.2M Sell
367,012
-96,762
-21% -$4.74M 0.06% 244
2021
Q1 		$22.9M Sell
463,774
-3,740
-0.8% -$187K 0.09% 206
2020
Q4 		$19.7M Sell
467,514
-1,601
-0.3% -$70.4K 0.08% 223
2020
Q3 		$21.5M Buy
469,115
+55,730
+13% +$2.7M 0.09% 194
2020
Q2 		$20.8M Buy
413,385
+69,503
+20% +$3.6M 0.09% 209
2020
Q1 		$17.7M Sell
343,882
-568
-0.2% -$30.3K 0.1% 185
2019
Q4 		$21.3M Buy
344,450
+4,511
+1% +$280K 0.1% 195
2019
Q3 		$20.4M Sell
339,939
-65,330
-16% -$4.85M 0.09% 214
2019
Q2 		$34.2M Buy
405,269
+14,793
+4% +$1.33M 0.16% 140
2019
Q1 		$37.3M Buy
390,476
+43,472
+13% +$3.9M 0.16% 138
2018
Q4 		$24.6M Sell
347,004
-99,671
-22% -$7.64M 0.12% 163
2018
Q3 		$38.2M Buy
446,675
+64,946
+17% +$6.51M 0.16% 138
2018
Q2 		$44.2M Buy
381,729
+160,344
+72% +$16M 0.19% 118
2018
Q1 		$17.9M Buy
221,385
+195,896
+769% +$15.1M 0.08% 215
2017
Q4 		$1.5M Buy
+25,489
New +$1.28M 0.01% 617
2017
Q2 		– Sell
-262,073
Closed -$8.07M – 1479
2017
Q1 		$8.07M Sell
262,073
-306,613
-54% -$9.55M 0.04% 330
2016
Q4 		$19M Buy
568,686
+199,389
+54% +$5.72M 0.09% 202
2016
Q3 		$9.83M Sell
369,297
-320,839
-46% -$7.45M 0.05% 276
2016
Q2 		$15.2M Sell
690,136
-117,738
-15% -$3.08M 0.08% 202
2016
Q1 		$23.7M Sell
807,874
-1,548
-0.2% -$43.1K 0.12% 183
2015
Q4 		$26.7M Buy
809,422
+73,787
+10% +$2.4M 0.14% 173
2015
Q3 		$26.6M Buy
735,635
+468,365
+175% +$20.1M 0.15% 165
2015
Q2 		$12M Buy
267,270
+264,304
+8,911% +$10.3M 0.06% 255
2015
Q1 		$91K Buy
+2,966
New +$115K ﹤0.01% 1037

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's ENTA Position: Q1 2026 in Review

Acadian Asset Management reduced its Enanta Pharmaceuticals (ENTA) stake by 0.58% in Q1 2026, selling an estimated $68.4K and leaving 880,023 shares worth $11.1M. The position accounts for 0.02% of the portfolio, ranked #506.

Acadian Asset Management first reported a position in ENTA in Q1 2015 and has held it in 40 quarters since. The position peaked at $44.2M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Acadian Asset Management held 880,023 shares of Enanta Pharmaceuticals worth $11.1M as of Q1 2026.
  • Acadian Asset Management sold 5,103 Enanta Pharmaceuticals shares in Q1 2026, an estimated $68.4K.
  • Enanta Pharmaceuticals made up 0.02% of Acadian Asset Management's portfolio in Q1 2026, its #506 holding.
  • Acadian Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 40 quarters since.
  • Acadian Asset Management's Enanta Pharmaceuticals position peaked at $44.2M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.